Jun 22, 2020
Immunic, Inc. to Join Russell 3000® Index
Jun 15, 2020
Immunic, Inc. Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19
Jun 10, 2020
Immunic, Inc. Announces Pricing of $25 Million Public Offering of Common Stock
Jun 09, 2020
Immunic, Inc. Announces Proposed Public Offering of Common Stock
Apr 21, 2020
Immunic, Inc. Reports that IMU-838, a Selective Oral DHODH Inhibitor, Has Demonstrated Preclinical Activity Against SARS-CoV-2 and Explores Plans for a Phase 2 Clinical Trial in COVID-19 Patients
Apr 17, 2020
Immunic, Inc. Announces Changes to Executive Team
Jan 08, 2020
Immunic Exercises its Option for the Exclusive Worldwide License to IMU-856 from Daiichi Sankyo Co., Ltd.
Dec 04, 2019
Immunic, Inc. to Present Data on IMU-856, for the First Time, at the Crohn's and Colitis Foundation's IBD Innovate Conference
Nov 25, 2019
Immunic, Inc. to Participate in Investor and Scientific Conferences in December
Nov 19, 2019
Immunic, Inc. Expands Board of Directors with Appointment of Biotechnology Executive Barclay A. Phillips
Nov 07, 2019
Immunic, Inc. Reports Third Quarter 2019 Financial Results and Highlights Recent Activity
Nov 05, 2019
Immunic, Inc. to Participate in Industry and Investor Conferences in November
Oct 15, 2019
Immunic, Inc. Expands Board of Directors with Appointment of Industry Veteran Tamar Howson
Oct 10, 2019
Immunic, Inc. Announces Completion of Enrollment for its Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis
Sep 30, 2019
Immunic, Inc. to Participate in Investor and Scientific Conferences in October
Sep 18, 2019
Immunic, Inc. Doses First Healthy Volunteer in its Phase 1 Clinical Program of IMU-935, a Potentially Best-in-Class RORgt Inverse Agonist
Sep 11, 2019
Immunic, Inc. to Present Selected Available and Previously Unpublished Data Regarding Lead Program, IMU-838, at the Congress of the European Committee for Treatment and Research in Multiple Sclerosis 2019
Sep 05, 2019
Immunic, Inc.'s Interim Dosing Analysis of IMU-838 as Part of its Ongoing Phase 2 CALDOSE-1 Study in Patients with Moderate-to-Severe Ulcerative Colitis Establishes Broad, Potentially Safe and Effective Dose Range
Sep 03, 2019
Immunic, Inc. to Participate in Scientific and Investor Conferences in September
Aug 12, 2019
Immunic, Inc. Announces First Patient Enrolled in Investigator-Sponsored Proof-of-Concept Clinical Trial of IMU-838 for the Treatment of Patients with Primary Sclerosing Cholangitis